We have established a novel quantitative method based on the allele-specific PCR, which uses the linearly amplified fragment of the PCR products as the internal control. The improved characteristics of the procedure are the high sensitivity for quantitation of the mutant alleles at ratios of up to 1:10 000 and the reduced necessity of the optimization of the PCR conditions for each mutation. Using this modified allele-specific PCR, we could quantify the tumor alleles in the urine sediments of three patients with urothelial cancers that harbored different p53 gene mutations. This method can be applied to other genetic targets that have other types of alterations, such as deletions or insertions.
Introduction
Several techniques based on the polymerase chain reaction (PCR) assay have been used to detect cancer cells present in such body fluids as the sputum, feces, urine and pancreatic juice [1] [2] [3] . Point mutations of the K-ras gene frequently are used as genetic markers in these molecular techniques [4] [5] [6] . Ras gene mutation, however, is not a clinically useful marker for urothelial cancers because it is an infrequent event [7] [8] [9] . Genetic alteration of the p53 tumor suppressor occurs frequently in urothelial cancers, particularly in the subset of tumors susceptible to recurrence and progression [10] [11] [12] [13] . We previously showed that in four independent cases of urinary tract carcinoma every one of a set of heterotopic multiple tumors, grown synchronously and asynchronously, harbored an identical mutation of the p53 gene [14] . This means that the multicentric recurrence of urothelial cancer is often brought about by intraluminal seeding of the initial tumor and that the genetic alteration of p53 is a promising molecular marker for the diagnosis of the recurrence of urothelial cancer.
The allele-specific PCR is a powerful and simple method [15] , as compared with the RNase cleavage assay, ASO hybridization and the PCR-SSCP assay, for detecting a small number of cancer cells in a large number of normal (non-cancerous) cells using point mutation as the marker. For allele-specific amplifica-tion, however, it is necessary to optimize such PCR conditions as the cycle number, annealing temperature and Mg 2+ concentration for each primer sequence to avoid mismatched amplification. Unlike those of the ras genes, the mutation sites of p53 gene are divergent [16] and modification of PCR conditions from one case to another is required, but this is impractical in a clinical setting. In the quantitative allele-specific PCR, quantitation of mismatched amplification can be substituted for the optimization of PCR conditions by defining the zero level. In this way, we detected cancer-derived DNAs in urine sediment cells from patients with urinary tract carcinomas up to the ratio of 1:10 000.
Materials and methods

Strategy
The method is shown schematically in Fig. 1 . Three fragments are generated from the template by the PCR, i.e. an exponentially amplified fragment and two linearly amplified fragments, which are usually disregarded except for asymmetric PCR. If a short fragment containing the region to be amplified is used in sufficient quantity for the template and a few cycles of PCR are required, these last two fragments become visible and measurable. In allele-specific PCR, the amount of exponentially amplified fragment is proportional to the amount of mutant allele. In contrast, the amount of one of the linearly amplified fragments generated with the paired primer is proportional to the total amount of all the alleles. We hypothesize that this fragment acts as an internal control in the allele-specific PCR and that the relative ratio of the intensity of the exponentially amplified fragment to that of the linearly amplified fragment indicates the ratio of the mutant allele to all the alleles. Thus, a quantitative allele-specific PCR method that uses the linearly amplified fragment as the internal control has been designed.
Template preparation
The genomic DNAs of the cultured cells of bladder cancer cell line 5637, white blood cells of normal volunteers, frozen tumor tissues and urine sediments of urinary tract tumors were extracted using the protocols for proteinase K digestion, phenol-chloroform extraction and ethanol precipitation described previously [17] . Fig. 1 . Schematic illustration of the quantitative allele-specific PCR. Genomic DNA carrying both mutant and normal alleles is amplified in the first round PCR (first step) to prepare the allelespecific PCR template. The product is expected to have both the mutant and normal alleles in the same ratio as the genomic DNA. There are three kinds of amplified fragments in the allele-specific PCR (second step), i.e. a linearly amplified fragment generated with the allele-specific primer which annealed to the template of the mutant allele, another linearly amplified fragment with the paired primer which annealed to the templates of the mutant and normal alleles and an exponentially amplified fragment, usually called the PCR product. The exponentially amplified fragment is proportional to the amount of mutant allele and the linearly amplified fragment generated with the paired primer is proportional to the amount of all the alleles. The relative intensity of the exponentially amplified fragment to the linearly amplified fragment therefore indicates precisely the ratio of mutant allele in the genomic DNA.
To obtain adequate templates for the quantitative allele-specific PCR, normal and tumor DNAs and the DNA from the urine sediments were amplified by the usual PCR technique (LA-taq; Takara Shuzo, Kyoto, Japan) with suitable primers [18] to include the point of mutation (Fig. 1, first step) , after which the residual primers were removed with an ultrafiltration kit (Suprec02; Takara Shuzo, Kyoto, Japan). Mixed solutions consisting of normal and mutant templates in various ratios were subjected to the quantitative allele-specific PCR.
Allele-specific PCR
Samples (30 ml) were of a PCR mixture containing 1.5-10 fmol of template, 10 pmol of allele-specific primer and paired primer (0.2 pmol of paired primer was labeled with 32 P), 200 mM of dATP, dGTP, dCTP and dTTP and 2.5 units of Taq polymerase without 3′ exonuclease activity (AmpliTaq, Perkin-Elmer Cetus) in buffer containing 1.5 mM MgCl 2 . Three to 20 cycles of the allele-specific PCR were run in an automatic programmable thermal cycler (DNA Thermal Cycler, Perkin-Elmer Cetus) at 94°C for 30 s, 64°C for 30 s and 72°C for 1 min. A stop solution was added to inhibit any further reaction, after which the samples were denatured at 94°C for 2 min and then chilled on ice.
A sample of the PCR products (2.5 ml) was electrophoresed on a 6% denaturing acrylamide gel at 30 V/ cm for 1 h. After the gel was dried, the intensities of the bands were measured with an imaging analyzer (BAS2000, Fujifilm, Tokyo, Japan) and the relative intensity was calculated, which is the ratio of the intensity of the exponentially amplified fragment to that of the linearly amplified fragment, and plotted against the known mutant allele ratio of template. A standard curve was obtained as a regression line by the least squares method. The relative efficiency of the mismatched extension compared to that of the matched extension was estimated as the ratio of the value for 0% to that for 100% calculated with the regression line.
Urinary tract tumors and urine sediments
After providing written informed consent, patients treated at our hospital usually undergo genetic analyses as follows. The nuclear accumulation of p53 is examined by immunohistochemistry, after which PCR-SSCP analysis and direct sequencing are performed on tumors showing positive p53 staining.
Three patients with urothelial carcinomas and one with leiomyosarcoma of the bladder, all of which harbored p53 mutations of different codons, were selected for this study (Table 1) . Urine sediment cells were collected by the centrifugation of 50 ml of urine collected prior to surgery. Urine analysis was done on 10 ml of the same urine. Quantitative allele-specific PCR was performed as described and the presence of mutant alleles in the urine sediment was estimated from the standard curve for each case. Each experiment was repeated three times. Table 1 Sequences of the allele-specific primers and the relative efficiency of mismatched extension 
Results
Establishment of the quantitative allele-specific PCR
We conducted a preliminary experiment on a mixture of DNA solutions extracted from cancer cells (human bladder cancer cell line 5637 harboring a p53 gene mutation at codon 280 in exon 8) and normal lymphocytes. Template fragments of 401 bp that included the mutation were made using the exon 8 sense and exon 9 antisense primers [18] in the first step PCR.
Mutant-normal DNA mixtures of different ratios were made and the allele-specific PCR was performed with the allele-specific primer for 5637 cells (Table 1) and the exon 8 antisense primer [18] as the paired primer. Different cycle numbers were chosen in relation to the percentages of mutant DNA (Fig. 2a-d) . In each assay, compared with the intensities of the exponentially amplified fragments, the relative intensities increased linearly together with the ratio of mutant allele in the templates. The relative efficiency of the mismatched to matched extension decreased with the number of cycles, 1/10 000 being obtained with 17 cycles of the allele-specific PCR. 
Application to other point mutations of the p53 gene
Similar experiments were performed using urothelial carcinoma tissue DNAs carrying three different p53 point mutations (Table 1) and their normal counterpart DNAs. Different allele-specific primers were used in each case, but template formation and allelespecific amplification were conducted under the same conditions as for the 5637 cells. For ratios from 0 to 100% of the mutant to total DNAs, the relative intensities of the allele-specific amplification increased linearly with the percentage of mutant DNAs (Fig. 3) . The relative efficiencies of mismatched extension, however, decreased with the allele-specific primer length (cases 1 and 2, 1/200; case 3, 1/400; and case 4, 1/2000; Table 1 ).
Quantitation of tumor-derived DNAs in urine sediments
Our modified allele-specific PCR was used to determine the percentage of tumor cells in the urine sediments of patients with urinary tract tumors (cases 1-4 in Tables 1 and 2 ). These tumors were histopathologically transitional cell carcinomas of grade 2 (cases 1-3) and a leiomyosarcoma (case 4). Because the percentages of the target cells in these materials was uncertain, three cycles were chosen at first for the second round amplification. As the band intensities were not strong enough to make an accurate estimation, seven cycles were adopted. The percentage of mutant alleles could be successfully quantified in urine sediments of the patients suffering from tumors 1, 2A and 2B, but the band intensities were still not strong enough for those of tumors 3 and 4. Quantitation was obtained at cycle 12 for that of tumor 3, but not until cycle 17 for that of tumor 4. The patient suffering from tumor 2A had a recurrent tumor (tumor 2B) in the bladder 6 months later. The allelespecific PCR, using the same primer as that used for tumor 2A, successfully detected tumor-derived DNAs in the urine sediment at the time of recurrence. Direct sequencing of DNA from tumor 2B afterwards showed that it had the same mutation as tumor 2A. Fig. 2b . The closed circle is the plot of the relative intensity of urine sediment and the amount of mutant allele in the urine sediment was estimated as 6.7% in this experiment (as shown with a broken line). Table 2 Quantitation of mutant allele in exfoliated cells in urine of urinary tract tumor patients 
Discussion
There have been a few quantitative allele-specific PCR studies. Liang et al. [19] , working with both mutant and wildtype-specific primers, compared the ratio of product yields obtained with those primers for quantitation. Horikoshi et al. [20] used a third primer co-operating with the paired primer of the allele-specific primer, which generated an endogenous internal control for quantitation. The lower limits for quantitation in these methods, in which the ratio of the exponentially amplified fragment to another exponentially amplified fragment was used for quantitation, were about 1:100 and 1:500. The measurable ranges are limited in most quantitative PCR techniques with internal controls because the intensities of the targets and internal controls must lie between the background level and the maximum measurable level on the image. In the quantitative allele-specific PCR presented here, both the intensities of the exponentially and linearly amplified fragments can be adjusted by cycle number to a suitable range in which the background noise is negligible even if the percentage of mutant allele in the sample is very small. For example, five cycles are suitable for a sample expected to contain 10% of mutant allele and 14 cycles are suitable for a 1% sample in order to value the intensities on the electrophoretic image. We found that with this method the maximum quantitation ratio is 1:10 000, which means that a single cancer cell harboring a mutation can be detected in the sediment of 50 ml of urine which usually contains 10 3 -10 4 cells. Differences in melting temperature, enzyme-affinity and elongation efficiency of the matched and mismatched templates are the factors responsible for allele-specific amplification [21, 22] . There are several ways to augment the effects of these differences, such as locating the mismatch at the 3′-end of the primer, shortening the primer length, placing additional mismatches in the primer close to the 3′-end, selecting a mismatched base pair, using a higher annealing temperature and decreasing the primer and dNTP concentrations [23, 24] . Most of these, however, decrease the PCR efficiency both for the mismatched and matched templates. To design an allele-specific primer as short as possible is considered a good way to overcome this problem. In our findings, the relative efficiency of mismatched extension was much lower with the shorter primer lengths (16 bases for case 3 and 14 bases for case 4) as compared to the longer primer lengths (21 bases for cases 1 and 2) ( Table 1) .
Because the internal control in this quantitative allele-specific PCR is endogenous and co-amplified equally to the specific allele with the outer pair of the primers, the strategy of nested PCR is available and it gives several advantages to the quantitative allele-specific PCR, i.e. (1) quantitation of the genomic DNAs in the samples is unnecessary, which is particularly advantageous when there is a small sample volume as in urine sediments, (2) there is little chance of the primer annealing to other unexpected sequences of the template in spite of the inflexible design of allele-specific primers, (3) anything that might affect PCR efficiency in the examined samples is removed or attenuated during the first round PCR and (4) only a few cycle numbers are required for adequate amplification. These advantages minimize the inter-assay fluctuation inherent in the PCR because of differences in primer sequences, annealing temperature and the concentrations of Mg 2+ and other agents.
The plateau phase, caused by consumption of the primers and other reactants, must be cautiously avoided as in most PCR-mediated quantitative methods because it reduces PCR efficiency and the ratios of the target/control intensities therefore will be underestimated. The values of 10% in Fig. 2c and 1% in Fig. 2d , representing the actual respective lower intensity ratios of 8.75 and 0.875%, are due to the plateau phase. The relationship between template dose and cycle number is the key to avoiding the plateau phase. The template doses were inversely proportional to the cycle number in this study. Because primer-dimer formation is a main reason for the unexpected early appearance of the plateau phase, the interval during which the reactants are mixed before starting the PCR should be short or alternatively a hot start technique is recommended. The hot start technique [25] prevents the non-specific annealing of primers at room temperature before the PCR is started by adding, mixing or activating the enzyme after the reaction mixture is heated.
The purpose of this study was to evaluate the possibility of the genetic diagnosis of urothelial cancers using urine sediments. It should be noted that our method could detect cancer-derived mutant alleles in urine sediments of two patients with cytologically negative tumors (tumors 1 and 2A). A major factor responsible for false negative results in urine cytology is the presence of inadequate cell numbers in urine. Sidransky et al. [1] identified p53 gene mutations in urine sediments of three patients with bladder cancer using allele-specific oligonucleotide plaque hybridization. They estimated that the percentages of cancer cells in their urine samples (volume unknown) were 1, 3 and 7%. These percentages are comparable to our findings. WBC contamination of urine sediments affects the detectability of mutant DNA. The low percentage (0.3%) of mutant DNAs estimated in urine sediments of the patient with tumor 3 might be due to the patient's severe pyuria.
The quantitative allele-specific PCR described here is a highly sensitive and reproducible method that can be used to detect microscopic lesions such as pathologically undetectable lymph node metastasis or disseminating malignant cells in the peripheral blood. This method is also applicable to genetic targets other than p53 and to other types of alterations such as deletion or insertion.
